<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02490904</url>
  </required_header>
  <id_info>
    <org_study_id>2015-000956-29</org_study_id>
    <nct_id>NCT02490904</nct_id>
  </id_info>
  <brief_title>Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)</brief_title>
  <acronym>EPURE</acronym>
  <official_title>Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation : Effect on Graft Function at 3 Months.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the impact of eplerenone (initiated within 2 hours prior to patient departure to the
      operating room and administered for 4 days during the post-operative period) on graft
      function evaluated by the measurement of glomerular filtration rate at 3 months - variable
      strongly associated with long-term graft survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">July 2030</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Iohexol clearance</measure>
    <time_frame>3 months</time_frame>
    <description>Graft function at 3 months evaluated by GFR using iohexol clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of dialysis dependency</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients presenting a delayed graft function</measure>
    <time_frame>7 days post transplantation</time_frame>
    <description>The proportion of patients with a delayed graft function defined by the need for one or more dialysis sessions during the 7 days following transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour proteinuria</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hyperkalemia &gt; 6 mmol/l</measure>
    <time_frame>7 days post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of initial hospital stay</measure>
    <time_frame>1 month</time_frame>
    <description>between transplantation and discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive</measure>
    <time_frame>3 months 1 year, 3 years, 10 years</time_frame>
    <description>vital status collected through the national database of organ recipients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum creatinine</measure>
    <time_frame>3 months 1 year, 3 years, 10 years</time_frame>
    <description>using the enzymatic method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glomerular filtration rate</measure>
    <time_frame>3 months 1 year, 3 years, 10 years</time_frame>
    <description>estimation using the CKD-EPI formula (in mL/min/1.73m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with immediate renal recovery,</measure>
    <time_frame>7 days post transplant</time_frame>
    <description>The proportion of patients with an immediate renal recovery is defined by a serum creatinine lower than 30 mg/L at 7 days post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iohexol clearance &lt; 30 mL/min/1,73m²</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour microalbuminuria</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a slow renal recovery</measure>
    <time_frame>7 days post transplant</time_frame>
    <description>The proportion of patients with slow renal recovery is defined by serum creatinine above 30 mg/L at 7 days post-transplant without the need for dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with biopsy-proven acute rejection</measure>
    <time_frame>3 months post transplant</time_frame>
    <description>Proportion of patients with biopsy-proven acute rejection in the first three month after transplantation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Eplerenone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone administration within 2 hours prior to patient departure to the operating room and for 4 days after kidney transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administration within 2 hours prior to patient departure to the operatingroom and for 4 days after kidney transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours</description>
    <arm_group_label>Eplerenone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Double-blinded Placebo administered for 4 days at 25mg every 12 hours</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years of age

          -  Informed consent

          -  Candidate for a single or a dual kidney transplantation from an expanded criteria
             deceased donor ( 60 years or older or age between 50 and 59 with 2 of the 3 following
             criteria: cardiovascular death, history of hypertension, serum creatinine above
             130µmol/L), regardless of machine perfusion and graft rank

          -  Chronic hemodialysis

          -  Affiliated to a social security system

        Exclusion Criteria:

          -  Multiple organ transplantation (kidney and liver, kidney and heart, kidney and
             pancreas, kidney and lung, kidney and intestine)

          -  Patient receiving a graft from a donor under mineralocorticoid receptor antagonist
             treatment (spironolactone or eplerenone)

          -  Peritoneal dialysis

          -  Preemptive transplantation

          -  Hypersensitivity or known allergy to Eplerenone or one of its excipients

          -  Patients with severe hepatic insufficiency (class Child-Pugh C)

          -  Patient receiving powerful CYP3A4 inhibitors (for example itraconazole, ketoconazole,
             ritonavir, nelfinavir, clarithromycin, telithromycyn and nefazodone)

          -  Hypersensitivity or known allergy to iodinated contrast agents (iohexol)

          -  Demonstrated thyrotoxicosis

          -  Hypersensitivity to lactose

          -  HLA desensitization prior to renal transplantation

          -  Pregnant woman or woman without effective contraception

          -  Patient under judicial protection

          -  Patient under legal guardianship

          -  Participation in another biomedical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric JAISSER, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie GIRERD, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédéric JAISSER, Doctor</last_name>
    <phone>+33 1 44278106</phone>
    <email>frederic.jaisser@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie GIRERD, Doctor</last_name>
    <phone>+33 383157322</phone>
    <email>s.girerd@chu-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier DUCLOUX</last_name>
    </contact>
    <investigator>
      <last_name>Didier DUCLOUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick LE MEUR, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Yannick LE MEUR, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon- Hôpital Bocage Central</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane MOUSSON</last_name>
    </contact>
    <investigator>
      <last_name>Christiane MOUSSON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie GIRERD</last_name>
    </contact>
    <investigator>
      <last_name>Sophie GIRERD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Reims-Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe RIEU</last_name>
    </contact>
    <investigator>
      <last_name>Philippe RIEU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe MARIAT, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Christophe MARIAT, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHC -CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno MOULIN</last_name>
    </contact>
    <investigator>
      <last_name>Bruno MOULIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2015</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney transplantation</keyword>
  <keyword>Eplerenone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

